Skip to main content Accessibility help
×
Home

P03-127 - A Flexible-Dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Other Oral Antipsychotics

  • A. Schreiner (a1), D. Hoeben (a2), M. Lahaye (a3), C. Tessier (a4), J. Peuskens (a5), F. Nardini (a6), W. Albrecht (a7), M. Jakovljevic (a8) and S. Djukic-Dejanovic (a9)...

Abstract

Objective

To explore tolerability, safety and treatment response of flexible doses of paliperidone ER in adult non-acute patients with schizophrenia previously unsuccessfully treated with oral antipsychotics.

Methods

International prospective 6-month open-label study. Endpoints were the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity Scale (CGI-S), patient satisfaction, adverse events (AEs), extrapyramidal symptoms (Extrapyramidal Symptom Rating Scale; ESRS) and weight change.

Results

1812 patients were included (59.9% male, mean age 40.1±12.6 years, 75.8% paranoid schizophrenia); most were enrolled because of lack of efficacy (n=1026) or lack of tolerability (n=490) with prior antipsychotic treatment. The median mode dose of paliperidone ER was 6 mg/day. 70.7% of patients completed the 6-month study. Most frequent reasons for early discontinuation were patient choice (8.8%), lack of efficacy or adverse event (5.1% each) independent of the reason for switching. Mean total PANSS decreased significantly from 79.4±20.4 at baseline to 66.1±21.5 at endpoint (mean change -13.3±19.7; 95% confidence interval -14.2;-12.3, p< 0.0001). The percentage of patients rated mildly ill or less in CGI-S increased from 27.0% to 52.2% at endpoint, and the rate of patients with mild functional impairment increased from 15.8% to 34.9%. AEs reported in greater-than-or-equal-to 5% of patients were insomnia (9.2%) and anxiety (7.2%). Extrapyramidal symptoms in ESRS decreased significantly from 3.5±5.8 to 2.1±4.6 (p< 0.0001). Mean weight gain from baseline to endpoint was 0.3±4.8kg.

Conclusion

These data support results from recent randomized controlled studies that paliperidone ER is safe, well tolerated and effective in patients previously unsuccessfully treated with other oral antipsychotics.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      P03-127 - A Flexible-Dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Other Oral Antipsychotics
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      P03-127 - A Flexible-Dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Other Oral Antipsychotics
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      P03-127 - A Flexible-Dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Other Oral Antipsychotics
      Available formats
      ×

Copyright

P03-127 - A Flexible-Dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Other Oral Antipsychotics

  • A. Schreiner (a1), D. Hoeben (a2), M. Lahaye (a3), C. Tessier (a4), J. Peuskens (a5), F. Nardini (a6), W. Albrecht (a7), M. Jakovljevic (a8) and S. Djukic-Dejanovic (a9)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

P03-127 - A Flexible-Dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Other Oral Antipsychotics

  • A. Schreiner (a1), D. Hoeben (a2), M. Lahaye (a3), C. Tessier (a4), J. Peuskens (a5), F. Nardini (a6), W. Albrecht (a7), M. Jakovljevic (a8) and S. Djukic-Dejanovic (a9)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *